HDAC9 and neoplasm: Surprisingly, we did see a large shift in responsiveness to depsipeptide, but not other HDAC inhibitors, in two cell lines, one derived from a lymph node lesion before chemotherapy treatment, the other derived from the primary tumour after exposure to etoposide and cisplatin.